Valuation: Abpro Corporation

Market Cap 5.31M 4.83M 4.45M 4.05M 7.6M 491M 7.99M 54.2M 21.54M 268M 19.91M 19.49M 842M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 5.39M 4.91M 4.52M 4.11M 7.71M 499M 8.11M 55.02M 21.87M 272M 20.21M 19.78M 855M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.31M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.24%-1.22%+33.67%+175.26% 44B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.90%

Financials

2024 2025
Net sales 183K 167K 154K 140K 262K 16.95M 275K 1.87M 743K 9.26M 687K 672K 29.05M -
Net income -7.23M -6.59M -6.07M -5.52M -10.36M -670M -10.89M -73.87M -29.36M -366M -27.13M -26.56M -1.15B -2.89M -2.63M -2.43M -2.21M -4.14M -268M -4.35M -29.54M -11.74M -146M -10.85M -10.62M -459M
Net Debt 478K 435K 401K 365K 685K 44.26M 719K 4.88M 1.94M 24.18M 1.79M 1.76M 75.87M 80K 72.86K 67.14K 61.07K 115K 7.41M 120K 817K 325K 4.05M 300K 294K 12.7M
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-